Cargando…
Therapy Selection for Hodgkin Lymphoma in Sickle Cell Disease: balancing risks and benefits
Advances in treatment have reduced mortality from Hodgkin lymphoma; therefore, greater attention should be focused on minimizing the late effects. A variety of risk-adapted treatment regimens exist that prioritize disease presentation but not patient-specific comorbidities. Herein, we describe a pat...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188625/ https://www.ncbi.nlm.nih.gov/pubmed/36459497 http://dx.doi.org/10.1182/bloodadvances.2022008245 |